Plain-English translation of NCT06702033 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a more personalized approach to treating HPV-related oropharyngeal cancer (cancer of the throat caused by the human papillomavirus). After surgery to remove the tumor, instead of giving all patients the same intensive combination of radiation and chemotherapy, doctors will assign you to a specific treatment plan based on what they find in your tumor tissue. The goal is to maintain cure rates while reducing the difficult side effects that come from standard treatment.
Most HPV-related throat cancers are highly curable with current treatment, but the standard therapy — surgery followed by radiation and chemotherapy — causes significant side effects that can affect quality of life for years. This trial explores whether a less intensive approach can work just as well for many patients, reducing harm without sacrificing the chance of cure.
You likely qualify if…
You likely don't qualify if…
First, you will have surgery to remove your tumor and nearby lymph nodes in your neck. After surgery, pathology testing will determine your risk category. Based on those results, you'll be assigned to one of three arms: some patients will receive radiation therapy alone at two different dose levels, while others will receive radiation plus a chemotherapy drug called . Radiation treatment lasts about 4 weeks, with visits 5 days a week. Your specific treatment plan will be designed based on how aggressive your tumor appears, with the goal of giving you the right amount of treatment — no more, no less — to cure your cancer while minimizing side effects.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States